Passage BIO, Inc. financial data

Symbol
PASG on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Commerce Square, 2005 Market Street, 39 Th Floor, Philadelphia, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 600 % -24%
Debt-to-equity 45.7 % +51.6%
Return On Equity -78.6 % -7.55%
Return On Assets -54 % +3.93%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.1M shares +11.8%
Common Stock, Shares, Outstanding 62.1M shares +13%
Entity Public Float 48.9M USD +4.49%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 60.4M shares +10.3%
Weighted Average Number of Shares Outstanding, Diluted 60.4M shares +10.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 25M USD -39.9%
Operating Income (Loss) -70.4M USD +35%
Net Income (Loss) Attributable to Parent -64.8M USD +36.5%
Earnings Per Share, Basic -1.07 USD/shares +42.5%
Earnings Per Share, Diluted -1.07 USD/shares +42.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.6M USD +73.1%
Assets, Current 78.8M USD -33.2%
Property, Plant and Equipment, Net 9.33M USD -39%
Operating Lease, Right-of-Use Asset 13.8M USD -18.1%
Other Assets, Noncurrent 463K USD +6.93%
Assets 102M USD -32%
Accounts Payable, Current 742K USD -42.8%
Employee-related Liabilities, Current 4.41M USD -33.6%
Contract with Customer, Liability, Current 8.23M USD
Liabilities, Current 19.4M USD +18.5%
Deferred Income Tax Liabilities, Net 4.45M USD -23.8%
Operating Lease, Liability, Noncurrent 21.8M USD -4.94%
Other Liabilities, Noncurrent 2M USD
Liabilities 41.2M USD +4.81%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8K USD
Retained Earnings (Accumulated Deficit) -659M USD -10.9%
Stockholders' Equity Attributable to Parent 61.3M USD -45%
Liabilities and Equity 102M USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.9M USD +15.7%
Net Cash Provided by (Used in) Financing Activities 8.74M USD
Net Cash Provided by (Used in) Investing Activities 25.3M USD +19%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 62.1M shares +13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 15.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 37.6M USD +73.1%
Deferred Tax Assets, Valuation Allowance 220M USD +9.49%
Deferred Tax Assets, Gross 224M USD +8.55%
Operating Lease, Liability 25.5M USD -3.11%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.7M USD +36%
Lessee, Operating Lease, Liability, to be Paid 41.2M USD -7.47%
Property, Plant and Equipment, Gross 19.1M USD -15.4%
Operating Lease, Liability, Current 3.69M USD +9.34%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.76M USD +2.82%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.88M USD +9.29%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 15.7M USD -13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.86M USD +2.82%
Deferred Tax Assets, Operating Loss Carryforwards 94.9M USD +24.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.97M USD +2.85%
Additional Paid in Capital 720M USD +2.08%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.08M USD -17.2%
Deferred Tax Assets, Net of Valuation Allowance 4.45M USD -23.8%
Share-based Payment Arrangement, Expense 5.82M USD -46.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%